Aligos director receives 5,860 stock options
Aligos Therapeutics director Bridget A. Martell received a grant of 5,860 stock options to buy common shares at an exercise price of $5.50 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aligos Therapeutics director Bridget A. Martell received a grant of 5,860 stock options to buy common shares at an exercise price of $5.50 per share. The options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company’s 2027 annual stockholder meeting, contingent on continued service.
Insider Trade Summary
Grant/Award: 5,860 shares
Grant/Award
1 txn
Insider
Martell Bridget A
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,860 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,860 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.
Key Figures
Options granted: 5,860 options
Exercise price: $5.50 per share
Underlying shares: 5,860 shares
+2 more
5 metrics
Options granted
5,860 options
Stock Option (Right to Buy) grant to director on June 25, 2026
Exercise price
$5.50 per share
Conversion or exercise price for the stock options
Underlying shares
5,860 shares
Common stock underlying the option grant
Post-grant derivative holdings
5,860 derivative securities
Total options held following this transaction
Option expiration
June 25, 2036
Expiration date of the granted options
Key Terms
Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 5.5000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares"
annual meeting financial
"immediately prior to the annual meeting in 2027 of the Issuer's stockholders"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
continuous service financial
"subject to continuous service to the Issuer through such vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aligos Therapeutics (ALGS) disclose in this Form 4?
Aligos Therapeutics reported a stock option grant to director Bridget A. Martell. She received options for 5,860 shares of common stock, reflecting routine equity-based director compensation rather than an open-market share purchase or sale.
How many Aligos Therapeutics (ALGS) options did the director receive?
Director Bridget A. Martell received 5,860 stock options. Each option represents the right to buy one share of Aligos Therapeutics common stock, bringing her total reported option holdings from this grant to 5,860 derivative securities following the transaction.
What is the exercise price of the new Aligos Therapeutics (ALGS) options?
The granted options have an exercise price of $5.50 per share. This is the price at which Bridget A. Martell can purchase Aligos Therapeutics common stock once the options have vested and become exercisable under the grant terms.
When do Bridget A. Martell’s Aligos Therapeutics (ALGS) options vest?
The options vest 100% on the earlier of the first anniversary of the grant date or immediately prior to Aligos Therapeutics’ 2027 annual stockholder meeting. Vesting is conditioned on her continuous service to the company through the applicable vesting date.
When do the new Aligos Therapeutics (ALGS) options expire?
The granted stock options expire on June 25, 2036. After this expiration date, Bridget A. Martell would no longer be able to exercise any unexercised options from this grant, even if they had previously vested according to the award’s terms.
Is this Aligos Therapeutics (ALGS) Form 4 an open-market trade?
No, the Form 4 reflects a compensation-related option grant, coded as a grant or award acquisition. It does not report an open-market purchase or sale of Aligos Therapeutics common stock by the director in the public markets.
AI-generated analysis. How Rhea-AI works. Not financial advice.
